Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Sponsor

Memorial Sloan Kettering Cancer Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT04552288

Collaborator

(none)

Enrollment

Locations

Arm

29.9

Anticipated Duration (Months)

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumor Solid Carcinoma Solid Tumor, Adult Hematologic Malignancy	Drug: Benralizumab	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients

Actual Study Start Date :

Sep 16, 2020

Anticipated Primary Completion Date :

Mar 16, 2023

Anticipated Study Completion Date :

Mar 16, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Participants with eosinophil-related cutaneous events Study participants will have grade 2/3 eosinophil-related cutaneous adverse events	Drug: Benralizumab All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.

Arm

Intervention/Treatment

Experimental: Participants with eosinophil-related cutaneous events

Study participants will have grade 2/3 eosinophil-related cutaneous adverse events

Drug: Benralizumab

All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.

Outcome Measures

Primary Outcome Measures

Percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events [4 weeks]
To evaluate the percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events to grade ≤1 resulting from checkpoint inhibitors (CPIs) or targeted therapies with absolute blood eosinophil counts of at least .3 K/mcl.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have pathologically or cytologically confirmed solid or hematologic cancers.
Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment.
Patients must have a cancer therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl.
Rash maculo-papular
Bullous dermatitis
Pruritus
Urticaria
Eczema
Patients must plan to continue on culprit drugs.
Patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion:
Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab.
Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib.
Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration
Adequate bone marrow, liver and renal function:
Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)
Serum creatinine ≤ 1.8 xULN or calculated creatinine clearance >45 ml/min
Platelet count > 50 K/mcL , hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) >1.0 K/mcL. Blood transfusion to meet the inclusion criteria will not be allowed.
ECOG performance status 0-1 (see Appendix C).
Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
Female patients are authorized to participate if they meet the following criteria:
Women of child bearing potential must meet both of the following conditions:
Have a negative serum pregnancy test prior to enrollment and within 14 days prior to administration of the investigational product (IP).
Patient must use an effective form of birth control (confirmed by the Investigator) throughout the study duration and within 16 weeks after last dose of IP.
Female subjects who cannot bear children as evidenced by one or more of the following:
Bilateral Oophorectomy
Bilateral Salpingectomy
Bilateral Salpingectomy-Oophorectomy
Hysterectomy
Menopause (no menses ≥ 1 year prior to treatment)
Surgical Sterilization (i.e., tubal ligation or blockage) Note: If criteria not met, patient should be regarded as having child bearing potential
Subject must be able to receive a subcutaneous injection.
New/worsening ercAE within 90 days prior to study enrollment. Note: This assessment will be performed by the treating investigator.

Exclusion Criteria:

Concurrent use of another investigational drug or device for the ercAE (i.e., outside of study treatment) during, or within 4 weeks of treatment.
Patients receiving prednisone ≥ 20mg a day.
Known use of anti-IL-5 agents or biologics for the treatment of asthma which are known to decrease blood eosinophil levels.
Patients cannot use new topicals or medications for indication of pruritus or skin rash
Known history of anaphylaxis to biologic therapy.
A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, that had not been treated with, or has failed to respond to, standard of care therapy.
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Active infection that would impair the ability of the patient to receive study treatment.
Women who are pregnant or breast-feeding.
Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Receipt of live attenuated vaccines 30 days prior to the date of randomization

° Receipt of inactive/killed vaccinations (e.g., inactive influenza) is allowed provided they were not administered within 1 week before/after any investigational product administration.

Known history of allergy or reaction to the investigational product formulation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Memoral Sloan Kettering Cancer Center	Basking Ridge	New Jersey	United States	07920
2	Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)	Commack	New York	United States	11725
3	Memorial Sloan Kettering Westchester	Harrison	New York	United States	10604
4	Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities)	Hauppauge	New York	United States	11788
5	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York	United States	10065